TCL Archive ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention January 10, 1997
TCL Archive Oncology Practice Group Leaves Allegheny For Former Rival UPCI; Will NSABP Follow? June 30, 2000
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004